AstraZeneca to expand cancer pipeline with $2.4B acquisition

Pharmaceutical company AstraZeneca plans to acquire biotech company Fusion Pharmaceuticals for up to $2.4 billion, Investopedia reported March 19. 

Read the full post on Becker's Hospital Review | Healthcare News & Analysis